David Sacerdoti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4757530/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Platelets in Non-alcoholic Fatty Liver Disease. Frontiers in Pharmacology, 2022, 13, 842636.	1.6	9
2	Hyperdynamic circulatory syndrome in a mouse model transgenic for SerpinB3. Annals of Hepatology, 2020, 19, 36-43.	0.6	1
3	Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction. Cardiovascular Research, 2020, 116, 1458-1472.	1.8	15
4	Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. American Journal of Gastroenterology, 2018, 113, 368-375.	0.2	82
5	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	1.0	29
6	Heterotopic Implantation of Decellularized Pulmonary Artery Homografts In A Rodent Model: Technique Description and Preliminary Report. Journal of Investigative Surgery, 2018, 31, 282-291.	0.6	2
7	Development of NASH in Obese Mice is Confounded by Adipose Tissue Increase in Inflammatory NOV and Oxidative Stress. International Journal of Hepatology, 2018, 2018, 1-14.	0.4	34
8	Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy. Acta Myologica, 2018, 37, 204-209.	1.5	7
9	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. International Journal of Cardiology, 2017, 231, 143-149.	0.8	22
10	Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis. Journal of Vascular Research, 2017, 54, 92-99.	0.6	33
11	Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. Clinical Rheumatology, 2017, 36, 391-399.	1.0	21
12	Heme Oxygenase Induction Suppresses Hepatic Hepcidin and Rescues Ferroportin and Ferritin Expression in Obese Mice. Journal of Nutrition and Metabolism, 2017, 2017, 1-11.	0.7	15
13	Clinical role of non-invasive assessment of portal hypertension. World Journal of Gastroenterology, 2017, 23, 1.	1.4	22
14	Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation. Hepatology, 2016, 64, 923-930.	3.6	18
15	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Internal and Emergency Medicine, 2016, 11, 1059-1066.	1.0	90
16	Efficacy and safety of treatment of acute nonmalignant portal vein thrombosis with subcutaneous fondaparinux in patients with cirrhosis and marked thrombocytopenia. Digestive and Liver Disease, 2016, 48, e25-e26.	0.4	3
17	EETs and HO-1 cross-talk. Prostaglandins and Other Lipid Mediators, 2016, 125, 65-79.	1.0	23
18	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57

#	Article	IF	CITATIONS
19	Clinical and biochemical determinants of the extent of liver steatosis in type 2 diabetes mellitus. European Journal of Gastroenterology and Hepatology, 2015, 27, 1386-1391.	0.8	3
20	Characterization of a murine model of cardiorenal syndrome type 1 by high-resolution Doppler sonography. Journal of Ultrasound, 2015, 18, 229-235.	0.7	5
21	Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins and Other Lipid Mediators, 2015, 120, 80-90.	1.0	39
22	Changes in gene expression of cytochrome P-450 in liver, kidney and aorta of cirrhotic rats. Prostaglandins and Other Lipid Mediators, 2015, 120, 134-138.	1.0	4
23	Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1903-1912.	1.0	36
24	Beyond scoring: a modern histological assessment of chronic hepatitis should include tissue angiogenesis. Gut, 2014, 63, 1366-1367.	6.1	6
25	Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy. Journal of Clinical Investigation, 2014, 124, 2410-2424.	3.9	124
26	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. World Journal of Gastroenterology, 2014, 20, 15756.	1.4	50
27	Excessive daytime sleepiness and hepatic encephalopathy: it is worth asking. Metabolic Brain Disease, 2013, 28, 245-248.	1.4	37
28	HO-1 Induction Improves The Type-1 Cardiorenal Syndrome in Mice With Impaired Angiotensin Il–Induced Lymphocyte Activation. Hypertension, 2013, 62, 310-316.	1.3	15
29	Role of HO/CO in the Control of Peripheral Circulation in Humans. International Journal of Hypertension, 2012, 2012, 1-4.	0.5	5
30	The Emerging Role of Heme Oxygenase and Its Metabolites in the Regulation of Cardiovascular Function. International Journal of Hypertension, 2012, 2012, 1-2.	0.5	10
31	Mesenteric arteries responsiveness to acute variations of wall shear stress is impaired in rats with liver cirrhosis. Scandinavian Journal of Gastroenterology, 2012, 47, 1003-1013.	0.6	5
32	Splenic Doppler Impedance Indices Estimate Splenic Congestion in Patients With Right-Sided or Congestive Heart Failure. Ultrasound in Medicine and Biology, 2012, 38, 21-27.	0.7	14
33	Increased EETs participate in peripheral endothelial dysfunction of cirrhosis. Prostaglandins and Other Lipid Mediators, 2012, 98, 129-132.	1.0	12
34	No association between the degree of liver steatosis and early signs of vasculopathy in T2DM. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, e11-e12.	1.1	6
35	Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats. Journal of Hepatology, 2011, 54, 258-264.	1.8	10
36	11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension. Prostaglandins and Other Lipid Mediators, 2011, 96, 72-75.	1.0	8

#	Article	IF	CITATIONS
37	Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver International, 2011, 31, 881-890.	1.9	21
38	Heme oxygenase: the key to renal function regulation. American Journal of Physiology - Renal Physiology, 2009, 297, F1137-F1152.	1.3	91
39	Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography. Journal of Ultrasound, 2009, 12, 1-5.	0.7	25
40	Hepatitis C virus reinfection in liver transplant patients: Evaluation of liver damage progression with echo-color doppler. Liver Transplantation, 2008, 14, 616-624.	1.3	10
41	New abdominal collaterals at ultrasound: A clue of progression of portal hypertension. Digestive and Liver Disease, 2008, 40, 62-67.	0.4	33
42	Natural heme oxygenase-1 inducers in hepatobiliary function. World Journal of Gastroenterology, 2008, 14, 6122.	1.4	53
43	Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium Channels Contributes to Mesenteric Vasodilatation in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 187-194.	1.3	62
44	Thrombosis of the portal venous system. Journal of Ultrasound, 2007, 10, 12-21.	0.7	36
45	11,12-Epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. Prostaglandins and Other Lipid Mediators, 2007, 82, 155-161.	1.0	44
46	Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. Scandinavian Journal of Gastroenterology, 2007, 42, 256-262.	0.6	29
47	157 Importance of splanchnic Doppler parameters for the evaluation of liver damage progression after HCV reinfection in liver transplant patients. Journal of Hepatology, 2006, 44, S67.	1.8	Ο
48	193 Carbon monoxide-mediated activation of large conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats with ascites. Journal of Hepatology, 2006, 44, S80.	1.8	0
49	Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. Clinical Gastroenterology and Hepatology, 2006, 4, 1395-1402.	2.4	10
50	Chronic CO levels has a beneficial effect on vascular relaxation in diabetes. Biochemical and Biophysical Research Communications, 2006, 340, 935-943.	1.0	45
51	The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations. Ultrasound in Medicine and Biology, 2006, 32, 1369-1375.	0.7	654
52	Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1999-H2002.	1.5	49
53	Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Alimentary Pharmacology and Therapeutics, 2005, 22, 433-439.	1.9	10
54	Heme Oxygenase Overexpression Attenuates Glucose-Mediated Oxidative Stress in Quiescent Cell Phase: Linking Heme to Hyperglycemia Complications. Current Neurovascular Research, 2005, 2, 103-111.	0.4	16

#	Article	IF	CITATIONS
55	Acute Liver Rejection: Accuracy and Predictive Values of Doppler US Measurements—Initial Experience. Radiology, 2005, 235, 651-658.	3.6	30
56	Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut, 2005, 54, 1630-1636.	6.1	34
57	Carbon Monoxide Signaling in Promoting Angiogenesis in Human Microvessel Endothelial Cells. Antioxidants and Redox Signaling, 2005, 7, 704-710.	2.5	107
58	Role of the Heme Oxygenases in Abnormalities of the Mesenteric Circulation in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 636-643.	1.3	29
59	Identification of 5,6-trans-Epoxyeicosatrienoic Acid in the Phospholipids of Red Blood Cells. Journal of Biological Chemistry, 2004, 279, 36412-36418.	1.6	52
60	Alterations in thyroid Doppler arterial resistance indices, volume and hormones in cirrhosis: relationships with splanchnic haemodynamics. Ultrasound in Medicine and Biology, 2004, 30, 19-25.	0.7	8
61	31 Heme oxygenase (HO) mediates hyporeactivity to phenylephrine (PE) in mesenteric vessels of experimental cirrhosis with ascites. Journal of Hepatology, 2004, 40, 13.	1.8	0
62	Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypoperfusion. Metabolic Brain Disease, 2003, 18, 51-62.	1.4	14
63	Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins and Other Lipid Mediators, 2003, 72, 51-71.	1.0	92
64	Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes. European Journal of Endocrinology, 2002, 146, 687-694.	1.9	13
65	ARTEROPORTAL FISTULAS BETWEEN THE ACCESSORY RIGHT HEPATIC, GASTRODUODENAL AND SUPERIOR MESENTERIC ARTERIES AND PORTAL VEIN: A DIFFICULT TECHNICAL PROBLEM TO OVERCOME IN LIVER TRANSPLANTATION. Transplantation, 2002, 73, 417-419.	0.5	1
66	Role of spleen enlargement in cirrhosis with portal hypertension. Digestive and Liver Disease, 2002, 34, 144-150.	0.4	208
67	Changes in porto-hepatic hemodynamics during acute rejection (AR) in patients with liver transplant (OLT). Journal of Hepatology, 2002, 36, 35.	1.8	1
68	Increase in thyroid resistance indices in cirrhosis: relationships with volume, hormones, and hemodynamics. Journal of Hepatology, 2002, 36, 64.	1.8	0
69	Effect of percutaneous transhepatic portal vein embolization of the right portal vein (PTPE) on intrahepatic arterial resistance in patients with cirrhosis. Journal of Hepatology, 2002, 36, 199.	1.8	0
70	Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypoperfusion. Metabolic Brain Disease, 2002, 17, 347-358.	1.4	16
71	Change in portal flow after liver transplantation: Effect on hepatic arterial resistance indices and role of spleen size. Hepatology, 2002, 35, 601-608.	3.6	95
72	The Heme Oxygenase/Carbon Monoxide System in Hepatobiliary Pathophysiology. , 2002, , 313-322.		0

#	Article	IF	CITATIONS
73	Primary prophylaxis of variceal bleeding in cirrhosis. European Journal of Gastroenterology and Hepatology, 2001, 13, 349-358.	0.8	16
74	Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound in Medicine and Biology, 2001, 27, 901-907.	0.7	63
75	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. European Journal of Clinical Investigation, 2001, 31, 603-609.	1.7	70
76	Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology, 2000, 31, 324-329.	3.6	127
77	The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis. Hepatology, 2000, 32, 930-934.	3.6	224
78	Prognostic Indicators of Risk for First Variceal Bleeding in Cirrhosis: A Multicenter Study in 711 Patients To Validate and Improve The North Italian Endoscopic Club (Niec) Index. American Journal of Gastroenterology, 2000, 95, 2915-2920.	0.2	109
79	Arterioportal Fistulas in Patients with Liver Cirrhosis: Usefulness of Color Doppler US for Screening. Radiology, 2000, 216, 738-743.	3.6	40
80	Short- and long-term changes in splanchnic hemo-dynamics after livertransplantation (OLT). Journal of Hepatology, 2000, 32, 50.	1.8	1
81	Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. European Journal of Gastroenterology and Hepatology, 1999, 11, 1221-1226.	0.8	12
82	Splenic impedance indices: A useful method to monitor patients after liver transplantation?. Hepatology, 1998, 27, 674-678.	3.6	19
83	Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. Journal of Hepatology, 1998, 28, 622-630.	1.8	66
84	Q-T Interval Prolongation in Liver Cirrhosis. Reversibility after Orthotopic Liver Transplantation International Heart Journal, 1998, 39, 321-329.	0.6	37
85	Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. Journal of Hepatology, 1997, 26, 305-311.	1.8	30
86	Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. Journal of Hepatology, 1997, 27, 986-992.	1.8	104
87	Possible mechanisms for changes of intrasplenic arterial impedance indices in portal hypertension. Hepatology, 1997, 26, 513-514.	3.6	9
88	Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE Journal of Clinical Investigation, 1997, 100, 1264-1270.	3.9	69
89	Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet, The, 1996, 348, 1677-1681.	6.3	131
90	Optimizing the time-frame for the definition of bleeding-related death after acute variceal bleeding in cirrhosis. European Journal of Gastroenterology and Hepatology, 1996, 8, 75-80.	0.8	1

#	Article	IF	CITATIONS
91	Splenic Doppler impedance indices: Influence of different portal hemodynamic conditions. Hepatology, 1996, 23, 1035-1040.	3.6	96
92	The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. Hepatology, 1996, 24, 820-823.	3.6	37
93	Left Ventricular Diastolic Function in Liver Cirrhosis. Scandinavian Journal of Gastroenterology, 1996, 31, 279-284.	0.6	143
94	The hemodynamic abnormalities in short-term insulin deficiency: the role of prostaglandin inhibition. Diabetes, 1996, 45, 602-609.	0.3	0
95	The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. Hepatology, 1996, 24, 820-823.	3.6	21
96	Splenic Doppler impedance indices: Influence of different portal hemodynamic conditions. Hepatology, 1996, 23, 1035-1040.	3.6	2
97	Relationship between portal blood flow measured by image-directed doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. Journal of Clinical Ultrasound, 1995, 23, 297-303.	0.4	18
98	Interobserver and interquipment variability of echo-doppler examination of the portal vein: Effect of a cooperative training program. Hepatology, 1995, 21, 428-433.	3.6	152
99	Paraumbilical vein patency in cirrhosis: Effects on hepatic hemodynamics evaluated by doppler sonography. Hepatology, 1995, 22, 1689-1694.	3.6	39
100	Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: Relationships with portal hemodynamics. Gastroenterology, 1995, 108, 1152-1158.	0.6	141
101	Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis*1, *2. Hepatology, 1995, 22, 808-813.	3.6	26
102	Interobserver and interequipment variability of echo-doppler examination of the portal vein: Effect of a cooperative training program. Hepatology, 1995, 21, 428-433.	3.6	122
103	Paraumbilical vein patency in cirrhosis: Effects on hepatic hemodynamics evaluated by Doppler sonography*1. Hepatology, 1995, 22, 1689-1694.	3.6	1
104	Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology, 1994, 19, 628-634.	3.6	79
105	Renal vasoconstriction in cirrhosis. Hepatology, 1994, 20, 539-541.	3.6	0
106	Circadian variation in the frequency of acute variceal bleeding in cirrhosis. Journal of Hepatology, 1994, 21, 912-913.	1.8	3
107	Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography. Hepatology, 1993, 17, 219-224.	3.6	100
108	A multicenter controlled study comparing beta-blockers and beta-blockers plus nitroderivatives in the primary prophylaxis of first variceal bleeding in cirrhosis: Interim analysis. Hepatology, 1993, 18, A283.	3.6	1

#	Article	IF	CITATIONS
109	Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography,. Hepatology, 1993, 17, 219-224.	3.6	2
110	Operators, machines, and a time interval variability of Echo-Doppler flowmetry for splanchnic hemodynamics. Hepatology, 1993, 18, A286.	3.6	0
111	Hepatic arterial resistance indices in cirrhosis with and without portal vein thrombosis. Hepatology, 1993, 18, A286.	3.6	1
112	Echo-Doppler evaluation of splanchnic and renal effects of nadolol (N) and isosorbide-5-mononitrate (I5M) in cirrhotics. Hepatology, 1993, 18, A280.	3.6	0
113	Effect of Acute and Chronic Treatment of Tin on Blood Pressure in Spontaneously Hypertensive Rats Tohoku Journal of Experimental Medicine, 1992, 166, 85-91.	0.5	16
114	Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology, 1992, 102, 973-979.	0.6	177
115	Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. Journal of Hepatology, 1992, 15, 299-303.	1.8	47
116	Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: Pathophysiological and clinical implications. Hepatology, 1992, 16, 1389-1394.	3.6	26
117	Role of atrial natriuretic peptide in the pathogenesis of sodium retention in IDDM with and without glomerular hyperfiltration. Diabetes, 1992, 41, 936-945.	0.3	7
118	Renal cytochrome P-450-dependent metabolism of arachidonic acid in cirrhotic rats. Journal of Hepatology, 1991, 12, 230-235.	1.8	7
119	Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. Journal of Hepatology, 1991, 12, 124-125.	1.8	33
120	Effects of Defibrotide on Renal Function and Urinary Prostanoid Excretion in Ciclosporin-Treated Rats. Nephron, 1991, 59, 477-481.	0.9	2
121	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	3.6	85
122	Impaired response to angiotensin II in Type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium countertransport activity. Diabetologia, 1991, 34, 595-603.	2.9	17
123	Chronic treatment with tin normalizes blood pressure in spontaneously hypertensive rats Hypertension, 1991, 17, 776-779.	1.3	68
124	Comparison of Sublingual Captopril and Nifedipine in Immediate Treatment of Hypertensive Emergencies. Archives of Internal Medicine, 1991, 151, 678.	4.3	36
125	Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Archives of Internal Medicine, 1991, 151, 678-682.	4.3	8
126	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	3.6	9

#	Article	IF	CITATIONS
127	Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney International, 1990, 38, 136-144.	2.6	213
128	Model for superconducting current in HTSC: How to calculate the maximum intrinsic values. Nuovo Cimento Della Societa Italiana Di Fisica D - Condensed Matter, Atomic, Molecular and Chemical Physics, Biophysics, 1990, 12, 857-861.	0.4	1
129	Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. European Journal of Clinical Investigation, 1990, 20, 111-117.	1.7	66
130	Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science, 1989, 243, 388-390.	6.0	265
131	The Renal Cytochrome P450 System Generates Novel Arachidonic Acid Metabolites. Advances in Experimental Medicine and Biology, 1989, 259, 109-129.	0.8	2
132	Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis. European Journal of Clinical Pharmacology, 1988, 34, 501-504.	0.8	9
133	Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function, and renin-aldosterone system in humans. Clinical Pharmacology and Therapeutics, 1988, 44, 211-216.	2.3	11
134	Renal cytochrome P-450-dependent metabolism of arachidonic acid in spontaneously hypertensive rats. Biochemical Pharmacology, 1988, 37, 521-527.	2.0	78
135	Differential Effects of Partial Hepatectomy on Hepatic and Renal Heme and Cytochrome P450 Metabolism. American Journal of the Medical Sciences, 1988, 296, 387-391.	0.4	23
136	Novel Renal Arachidonate Metabolites. American Journal of the Medical Sciences, 1988, 295, 268-274.	0.4	16
137	Nadolol for Prevention of Variceal Rebleeding in Cirrhosis: A Controlled Clinical Trial. Digestion, 1987, 37, 22-28.	1.2	65
138	Longâ€ŧerm effects of betaâ€adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics. Clinical Physiology, 1987, 7, 377-387.	0.7	6
139	Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. Journal of Hepatology, 1987, 4, 174-180.	1.8	55
140	Renal effects of nadolol in cirrhosis. European Journal of Clinical Pharmacology, 1987, 33, 473-477.	0.8	6
141	Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 667-672.	0.6	12
142	Effect of nadolol on liver haemodynamics and function in patients with cirrhosis British Journal of Clinical Pharmacology, 1986, 21, 713-719.	1.1	26
143	Redistribution of renal blood flow in patients with liver cirrhosis. Journal of Hepatology, 1986, 2, 253-261.	1.8	21
144	Blood flow of experimental liver metastases in rat as evaluated by the locally injected 133-Xenon washout. Research in Experimental Medicine, 1985, 185, 207-215.	0.7	6

#	Article	IF	CITATIONS
145	Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. American Heart Journal, 1984, 108, 1167-1172.	1.2	42
146	Renal Haemodynamics in Essential Hypertension Assessed by 133-Xenon Washout and Selective Renal Angiography. Angiology, 1982, 33, 818-824.	0.8	4